# Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

> **NCT01773278** · PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 100 (estimated)

## Conditions studied

- Smith-Lemli-Opitz Syndrome
- Cone-Rod Dystrophy
- Hearing Loss

## Interventions

- **DRUG:** Antioxidants
- **DRUG:** Cholesterol

## Key facts

- **NCT ID:** NCT01773278
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2008-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773278, "Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01773278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*